#United States #Somerset #Cardiovascular Care #Terumo Health Outcomes #Medis Medical Imaging

Terumo Health Outcomes and Medis Medical Imaging Join Forces

In a groundbreaking announcement, Terumo Health Outcomes (THO) has entered a strategic partnership with Medis Medical Imaging aimed at transforming cardiovascular care in the United States. This collaboration combines the innovative ePRISM™ precision medicine software platform developed by Terumo with Medis’ cutting-edge Quantitative Flow Ratio (QFR) technology.

Enhancing Patient Outcomes

The alliance intends to enhance cardiovascular patient care by utilizing a non-invasive, image-based assessment of coronary physiology. Specifically, the QFR technology provides valuable insights derived from angiographic images, effectively eliminating the need for more invasive wire-based techniques traditionally used in coronary artery disease (CAD) assessments. Currently, over 60 million individuals globally live with CAD, making this partnership not only timely but potentially life-saving.

At the heart of this collaboration is a commitment to improving clinical decision support capabilities. The combination of ePRISM and Medis QFR technology will be piloted at specialized clinical sites, aiming to utilize real-time data from electronic health records to enhance patient diagnostics. This streamlined approach promises to deliver more precise anatomical and physiological assessments, optimizing the interventional cardiologists' work in diagnosing and treating CAD.

A Proven Track Record

The efficacy of Medis' QFR technology is supported by a range of clinical trials. For instance, the FAVOR trials conducted in Europe demonstrated its effectiveness in reducing major adverse cardiac events (MACE) significantly—up to a 34% reduction after a year when compared to traditional angiography-guided procedures. Such achievements not only bolster confidence in this technology but also highlight its growing influence in cardiovascular methodology guidelines.

The recent addition of Medis QFR within the 2024 European Society of Cardiology guidelines underscores its importance and approval for usage in clinical practices. This collaboration bets on the next-generation QFR technology, which will be evaluated in the ongoing PIONEER IV trial, aimed at further enhancing pre- and post-procedure stenting recommendations through its integration with ePRISM.

Pioneering the Future of Cardiovascular Imaging

The commitment to innovation is palpable in statements made by key figures in this partnership. Ryan Graver, Senior Divisional Vice President at THO, emphasized the collaboration's goal of building a comprehensive solution that not only assures improved clinical outcomes but also simplifies workflows and enhances efficiency in the care delivery pathway.

Maya Barley, CEO of Medis Medical Imaging, added that this partnership aims to push the boundaries of diagnostic accuracy and treatment planning. By leveraging shared expertise and innovative technologies, both companies are dedicated to fostering improvements in cardiovascular care that can benefit clinicians and patients alike.

Advantages of Integrated Technology

Terumo's ePRISM platform is designed to assess patient risk and optimize treatment strategies while Medis provides robust imaging solutions. Together, they form a comprehensive suite that enhances efficiency and efficacy throughout medical procedures, ensuring informed decision-making for clinicians.

The implications of this partnership extend beyond improved clinical outcomes; they also encompass potential reductions in healthcare costs and recovery times for patients. With both Terumo and Medis sharing the aim of delivering high-quality, patient-centered care, this strategic partnership is poised to redefine practices in the cardiovascular sector.

As Terumo approaches its centenary in medical technology, this partnership reflects its enduring commitment to societal contributions through healthcare, combining innovation and clinical expertise to meet the complex needs of today’s patients.